Alfredo Carlo Altamura1, Marta Serati, Massimiliano Buoli. 1. Alfredo C Altamura, Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico , Via F. Sforza 35, 20122, Milan , Italy.
Abstract
BACKGROUND: An increasing number of studies identifies the duration of illness (DI) as an important predictor of outcome in patients affected by major psychoses (MP). The aim of the present paper was to revise medical literature about DI and its effects on MP, focusing in particular on the relationship between DI and outcome with particular reference to treatment response, suicidal risk, cognitive impairment and social functioning. METHODS: A search in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while papers considering other variables such as duration of untreated episode/illness were excluded. MP included the diagnoses of schizophrenia, bipolar disorder and major depressive disorder. RESULTS: Available data show that DI influences treatment response, suicidal risk and loss of social functioning in schizophrenic patients, while results are more controversial with regard to cognitive impairment. In bipolar disorder, a long DI has been associated with less treatment response, more suicidal risk and cognitive impairment, but more data are needed to draw definitive conclusions. Finally, studies, regarding DI of illness and its predictive value of outcome in major depressive disorder show contradictory results. CONCLUSIONS: DI appears a negative outcome factor particularly for schizophrenia, while with regard to mood disorders, more data are needed to draw definitive sound conclusions.
BACKGROUND: An increasing number of studies identifies the duration of illness (DI) as an important predictor of outcome in patients affected by major psychoses (MP). The aim of the present paper was to revise medical literature about DI and its effects on MP, focusing in particular on the relationship between DI and outcome with particular reference to treatment response, suicidal risk, cognitive impairment and social functioning. METHODS: A search in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while papers considering other variables such as duration of untreated episode/illness were excluded. MP included the diagnoses of schizophrenia, bipolar disorder and major depressive disorder. RESULTS: Available data show that DI influences treatment response, suicidal risk and loss of social functioning in schizophrenicpatients, while results are more controversial with regard to cognitive impairment. In bipolar disorder, a long DI has been associated with less treatment response, more suicidal risk and cognitive impairment, but more data are needed to draw definitive conclusions. Finally, studies, regarding DI of illness and its predictive value of outcome in major depressive disorder show contradictory results. CONCLUSIONS: DI appears a negative outcome factor particularly for schizophrenia, while with regard to mood disorders, more data are needed to draw definitive sound conclusions.
Entities:
Keywords:
Duration of illness (DI); Major psychoses (MP); Outcome
Authors: Hui-Xin Hu; Wilson Y S Lau; Eugenia P Y Ma; Karen S Y Hung; Si-Yu Chen; Kin-Shing Cheng; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan Journal: Schizophr Bull Date: 2022-06-21 Impact factor: 7.348
Authors: Luis Gutiérrez-Rojas; Sergio Sánchez-Alonso; Marta García Dorado; Paola M López Rengel Journal: CNS Drugs Date: 2022-04-23 Impact factor: 6.497
Authors: Martin A Katzman; Andrew A Nierenberg; Dalia B Wajsbrot; Ellen Meier; Rita Prieto; Elizabeth Pappadopulos; Joan Mackell; Matthieu Boucher Journal: J Clin Psychopharmacol Date: 2017-10 Impact factor: 3.153
Authors: Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier Journal: Int J Neuropsychopharmacol Date: 2018-02-01 Impact factor: 5.176